Lumiracoxib (Novartis)

Ding, C and Jones, G (2002) Lumiracoxib (Novartis). IDrugs, 5 (12). pp. 1168-1172. ISSN 1369-7056

Preview

PDF - Requires a PDF viewer
95Kb

Official URL: http://www.biomedcentral.com/1369-7056/5?issue=12

Abstract

Lumiracoxib, an inhibitor of cyclooxygenase 2 (COX-2), is under development by Novartis for the potential treatment of osteoarthritis, rheumatoid arthritis and pain. By late December 2000, phase III trials had been initiated and were ongoing in December 2001.

Item Type:	Article
Fields of Research 2008:	UNSPECIFIED
Subjects:	320000 Medical and Health Sciences > 320500 Pharmacology and Pharmaceutical Sciences > 320503 Clinical Pharmacology and Therapeutics
SEO 2008:	UNSPECIFIED
SEO:	UNSPECIFIED
Collections:	UNSPECIFIED
ID Code:	3523
Deposited By:	Dr Changhai / C Ding
Deposited On:	14 Mar 2008 11:23
Last Modified:	18 Jul 2008 20:41
ePrint Statistics:	View statistics for this ePrint

Repository Staff Only: item control page